跳至主要内容
临床试验/NCT04264962
NCT04264962已完成早期 1 期

Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter

Beijing Ditan Hospital1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2017年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
发起方
入组人数
300
试验地点
1
主要终点
Recurrance rate

研究概览

简要总结

Clinical research of Yang Yin Fu Zheng Jie Du therapy in recurrence of Hepatocellular Carcinoma less than 3 cm in diameter.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy in 1 year recurrence for patients belong to Hepatocellular Carcinoma less than 3 cm in diameter.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Meet the criteria of hepatocellular carcinoma
  • Ages Eligible for Study: ≤75 years old;
  • The size of the main nodule and multi-centricity (single lesion, three nodules ≤3 cm)
  • After transarterial chemoembolisation (TACE) or radiofrequency ablation (RFA)
  • Surgery cannot be allowed;
  • Informed consent from the patient.

排除标准

  • Serious problem of heart, lung, or kidney with severe dysfunction;
  • Pregnant or child breast feeding women;
  • Mental or cognitive disorders;
  • Participating in other drug trials;
  • Who are allergic to the study drug.

研究组 & 干预措施

Yang Yin Fu Zheng Jie Du therapy

Experimental

干预措施: Yang Yin Fu Zheng Jie Du therapy (Drug)

Yang Yin Fu Zheng Jie Du therapy

Experimental

干预措施: Routine medical care (Other)

Routine medical care

Placebo Comparator

干预措施: Routine medical care (Other)

结局指标

主要结局

Recurrance rate

时间窗: 1 year

次要结局

  • Objective response rate(1 year)
  • quality of life (QOL) questionnaire(1 year)

研究者

发起方
Beijing Ditan Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhiyun Yang

Archiater, Professor

Beijing Ditan Hospital

研究点 (1)

Loading locations...

相似试验